Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic ...

The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c) (4).

Diyar United is a respected distributor in Kuwait with extensive healthcare experience. Its strong network, supported by proven logistics and regulatory expertise, makes it a reliable partner to drive ...

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market ...

First report of high-resolution structures of DCAF2 - - Frontier™ Platform key to discovering covalent ligands to selectively target DCAF2 - BOSTON and SOUTH SAN FRANCISCO, Ca ...

By using both Frictional Energy Absorber Effectiveness (FEAE) and Finite Element Modelling (FEM), the results confirmed the mechanism of action of ALLEVYN COMPLETE CARE Dressing in mitigating ...

Title: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation Abstract Number: 862 Session Date and Time: Nov. 8, 2025; ...

FDA-approved non-invasive treatment for depression and OCD now available at Contemporary Care’s Naples clinic ...

Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance Abstract Number: 353 Location: Prince George ABC Exhibit Halls Gaylord ...

Xilio plans to present clinical data for vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa (XTX301), a tumor-activated IL-12, and plans to present ...